BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27167831)

  • 1. Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.
    Mugii N; Hasegawa M; Matsushita T; Hamaguchi Y; Oohata S; Okita H; Yahata T; Someya F; Inoue K; Murono S; Fujimoto M; Takehara K
    PLoS One; 2016; 11(5):e0154746. PubMed ID: 27167831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores.
    McCann LJ; Garay SM; Ryan MM; Harris R; Riley P; Pilkington CA
    Rheumatology (Oxford); 2007 Aug; 46(8):1363-6. PubMed ID: 17569746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
    Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
    J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NanoString technology distinguishes anti-TIF-1γ
    Preusse C; Eede P; Heinzeling L; Freitag K; Koll R; Froehlich W; Schneider U; Allenbach Y; Benveniste O; Schänzer A; Goebel HH; Stenzel W; Radke J
    Brain Pathol; 2021 May; 31(3):e12957. PubMed ID: 34043263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
    Fujimoto M; Hamaguchi Y; Kaji K; Matsushita T; Ichimura Y; Kodera M; Ishiguro N; Ueda-Hayakawa I; Asano Y; Ogawa F; Fujikawa K; Miyagi T; Mabuchi E; Hirose K; Akimoto N; Hatta N; Tsutsui K; Higashi A; Igarashi A; Seishima M; Hasegawa M; Takehara K
    Arthritis Rheum; 2012 Feb; 64(2):513-22. PubMed ID: 21987216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
    Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
    Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
    Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
    Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
    Kubeček O; Soukup T; Paulík A; Kopecký J
    BMC Cancer; 2016 Aug; 16(1):684. PubMed ID: 27561848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapidly progressive interstitial lung disease combined with pneumocystis jiroveci pneumonia in a patient with single anti-TIF-1γ antibody positive dermatomyositis in the context of an underlying tumor.
    Zhang H; Yue J; Hou X; Lu H; Bikdeli A; Guo H; Li H; Li D
    BMC Pulm Med; 2023 Jul; 23(1):248. PubMed ID: 37415133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice.
    Mariscal A; Milán M; Baucells A; Martínez MA; Guillen AG; Trallero-Araguás E; Alvarado-Cardenas M; Martínez-Martínez L; Alserawan L; Franco-Leyva T; Sanz-Martínez MT; Viñas-Giménez L; Corominas H; Juárez C; Castellví I; Selva-O'Callaghan A
    Front Immunol; 2020; 11():625896. PubMed ID: 33613568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.
    Kang EH; Kuwana M; Okazaki Y; Lee EY; Lee YJ; Lee EB; Song YW
    Mod Rheumatol; 2014 Nov; 24(6):945-8. PubMed ID: 24670134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
    Best M; Molinari N; Chasset F; Vincent T; Cordel N; Bessis D
    Acta Derm Venereol; 2019 Mar; 99(3):256-262. PubMed ID: 30460368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy.
    Harada Y; Tominaga M; Iitoh E; Kaieda S; Koga T; Fujimoto K; Chikasue T; Obara H; Kakuma T; Ida H; Kawayama T; Hoshino T
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between swallowing-related and limb muscle involvement in dermatomyositis patients.
    Kim SJ; Han TR; Jeong SJ; Beom JW
    Scand J Rheumatol; 2010 Aug; 39(4):336-40. PubMed ID: 20476862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
    Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
    J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis.
    Kato T; Ito S; Tsuzuki T; Watanabe D; Kubo A; Yamaguchi E
    Respirol Case Rep; 2019 May; 7(4):e00412. PubMed ID: 30906559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].
    Bodoki L; Budai D; Nagy-Vincze M; Griger Z; Betteridge Z; Dankó K
    Orv Hetil; 2015 Sep; 156(36):1451-9. PubMed ID: 26320599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rare Case of Anti-TIF-1γ Antibody Positive Dermatomyositis in Adulthood.
    Agrawal U; Sondhi M; Zamora Smith A; Nida SS; Umer S; Hayat S; Muzaffar K
    J Investig Med High Impact Case Rep; 2024; 12():23247096241263065. PubMed ID: 38904327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review.
    Kilinc OC; Ugurlu S
    Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.